Continuing Medical Education (CME)

"Imaging of Neuroendocrine Tumors and Obstacles to Diagnosis," Free Webinar

NOTE:  The archived webinar, presented live on August 22, 2012, is available as of November 15, 2012 at the link below

Eric H. Liu, MD, Director of the Neuroendocrine Center, Assistant Professor of Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN (pictured below)

Credit:  1.0 AMA PRA Category 1 (available for physician credit only)

A certified one-hour live webinar for radiologists, oncologists, gastroenterologists, endocrinologists, and other healthcare providers who diagnose and treat patients with NETs. The webinar is jointly sponsored by Postgraduate Institute for Medicine International Center for Postgraduate Medical Education and NANETS, the North American Neuroendocrine Tumor Society.

Objectives:

At the conclusion of this activity, participants should be better able to:

• Discuss the array of symptoms by which neuroendocrine tumors (NETs) can present, as well as the multiple locations NETs typically occur.

• Identify a provisional diagnosis of NETs when patients present with nonspecific complaints that cannot be resolved or complaints that are lumped into a syndrome.

• Describe the diagnostic tools necessary to confirm the presence of NETs.

Click here for more information and to register.

Pancreatic Neuroendocrine Tumors from Medscape Education Oncology

Jonathan R. Strosberg, MD
CME Released 6/29/2012, Valid for credit through 6/29/2013

This activity is intended for oncologists, hepatologists, gastroenterologists, radiation oncologists, surgical oncologists, pathologists, and other clinicians involved in the treatment of patients with gastrointestinal (GI) cancer.

The goal of this activity is to disseminate and analyze new data about GI cancer from the Chicago annual meeting so that clinicians involved in caring for patients with GI cancer will be able to assess the near- or long-term applicability of these data to their practice.

Upon completion of this activity, participants will be able to:

Analyze treatment strategies for GI cancers, including the relevance of molecular markers in selecting treatment and targeted therapies, and assess how they might affect current practice

Click here for more information.

NET Management Strategies:  What's New and Relevant?

This forum, to be held October 11 - 13, 2012 in San Diego, California, is designed for physicians and other health professionals from a variety of practice settings and levels to include the specialties of oncology, endocrinology, surgery, pathology, internal medicine, gastroenterology, research, diagnostic radiology, interventional radiology, pulmonology, nuclear medicine and primary care. Please register early as enrollment will be limited.

ACCREDITATION: This activity is currently being planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center and the North American Neuroendocrine Tumor Society. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

Nursing continuing education (CEU) contact hours will be provided by UCSD.

Click here for more information.

Liver-Directed Therapies in Patients With Advanced Neuroendocrine Tumors

Natalie B. Jones, MD; Manisha H. Shah, MD; Mark Bloomston, MD
CME Released: 06/04/2012; Valid for credit through 06/04/2013, From JNCCN -- Journal of the National Comprehensive Cancer Network

This activity is intended for primary care physicians, oncologists, gastroenterologists, surgeons, and other physicians who care for patients with NETs. The goal of this activity is to evaluate treatment strategies for liver metastases of NETs. Upon completion of this activity, participants will be able to:

1. Distinguish the most important prognostic factor for survival in cases of NETs
2. Analyze surgical options for the treatment of liver metastases associated with NETs
3. Assess the use of embolization of liver metastases associated with NETs
4. Evaluate other treatment modalities of liver metastases associated with NETs

Click here for more information.

A New Era for the Systemic Therapy of Neuroendocrine Tumors

This is an Oncologist CME Online, released on March 28, 2012, expiring on March 28, 2014.

The learning objectives are:

1. Describe the underlying biology of neuroendocrine tumors including pancreatic neuroendocrine tumors (PNETs) and carcinoids and the importance of these biologic features in the evolution of new drugs for these diseases.
2. Cite the historical data regarding the use of cytotoxic agents in the treatment of pancreatic neuroendocrine tumors and carcinoids.
3. Explain the significance of recent clinical trials utilizing biologic agents, in particular octreotide, the small molecule tyrosine kinase inhibitor, sunitinib and the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and how these medications have altered the natural history of both pancreatic neuroendocrine tumors and carcinoids.

ACCREDITATION and CREDIT DESIGNATION

The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.

The Society for Translational Oncology designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CLICK HERE for further information.

Management of Neuroendocrine Tumors of Unknown Origin

Ariel Polish, MD; Maxwell T. Vergo, MD; Mark Agulnik, MD
CME Released: 12/09/2011; Valid for credit through 12/09/2012
Continue to Activity

This activity is intended for primary care clinicians, internists, endocrinologists, neurologists, oncologists, and other healthcare professionals caring for patients with NETs of unknown origin.

The goal of this activity is to describe the evaluation and management of NETs of unknown origin.

Upon completion of this activity, participants will be able to:

• Describe the clinical and epidemiologic features of NETs and NETs of unknown origin on the basis of a review

• Describe the diagnostic workup of NETs of unknown origin on the basis of a review

• Describe the treatment of NETs of unknown origin on the basis of a review

This activity is jointly sponsored by Medscape, LLC and JNCCN -- The Journal of the National Comprehensive Cancer Network.

CLICK HERE for more information.

Penn Neuroendocrine Tumor Symposium

The Penn Neuroendocrine Tumor Symposium, a CME-certified course, will be held on Friday, September 9, 2011 at the University of Pennsylvania, Biomedical Research Building II/III, 421 Curie Boulevard, Philadelphia, Pennsylvania.

This conference is designed for endocrinologists, internists, oncologists, gastroenterologists, geneticists, nephrologists, pathologists, radiologists, specialists in nuclear medicine, physician assistants, nurses, nurse practitioners and other allied health professionals. Click here for a conference brochure.

For further information about the University of Pennsylvania Continuing Medical Education, click here. For further information about the conference, call 215-898-9800 or 215-898-8005; or send an email to penncme@mail.med.upenn.edu.

NET Diagnosis & Treatment: A New Era - A New Direction

This forum, to be held October 20 - 22, 2011 in Minneapolis, Minnesota, is designed for physicians and other health professionals from a variety of practice settings and levels to include the specialties of oncology, endocrinology, surgery, pathology, internal medicine, gastroenterology, research, diagnostic radiology, interventional radiology, pulmonology, nuclear medicine, and primary care. Please register early as enrollment will be limited.

ACCREDITATION: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas M.D. Anderson Cancer Center and the North American Neuroendocrine Tumor Society (NANETS). The University of Texas M.D. Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

Nursing continuing education contact hours will be provided.

For more information, click here.

Ohio State's Multidisciplinary Management of Neuroendocrine Cancers: From Standard of Care to Cutting Edge Therapies

This review of state-of-the-art evidence-based information on the diagnosis and management of neuroendocrine cancers is for specialists, primary care physicians, surgeons, radiologists, nurses, and other healthcare professionals who diagnose and treat patients with neuroendocrine cancer.  The meeting, scheduled for December 3, 2011 at the Hilton Columbus at Easton in Ohio, will focus on the needs and practice gaps in physician practice to improve patient outcomes by promoting multidisciplinary teams to address clinical and patient issues. The featured guest speakers are Dr. Thomas O'Dorisio, University of Iowa; Dr. Diane Reidy-Lagunes, Memorial Sloan Kettering Cancer Center; and Dr. James Yao, University of Texas MD Anderson Cancer Center.

The course directors are Dr. Mark Bloomston, Associate Professor of Surgery, Ohio State University, James Cancer Center, and Dr. Manisha Shah, Associate Professor of Internal Medicine, Ohio State University, James Cancer Center.

For an agenda and more information, click here.

Redefining Therapeutic Paradigms for Advanced Gastroenteropancreatic Neuroendocrine Tumors

This is an interactive case-based series that will provide participants with an overview of the most recent advances in the evaluation, imaging, prognosis, treatment, and biochemical monitoring of advanced gastroenteropancreatic neuroendocrine tumors (NETs), as well as specific updates and outcomes of ongoing clinical trials. This continuing education program will be implemented September – December 2011. For more information, click here.

This program is presented by Educational Concepts Group, LLC (ECG) and is supported by an educational grant from Novartis.

Endocrine Self-Assessment Tool - Multidisciplinary Approach to Management of Neuroendocrine Tumors

This continuing medical education activity, presented by The Endocrine Society, should be of substantial interest to endocrinologists, endocrine fellows and any healthcare professional treating patients with neuroendocrine tumors. Click here for more information.

The activity expiration date is December 2011.

For questions regarding CME content or obtaining CME credit, please contact The Endocrine Society, 301-941-0200 or education@endo-society.org.